…
Integer Holdings Corporation operates as a medical device outsource manufacturer in the United States, Puerto Rico, Costa Rica, and internationally. It operates through Medical and Non-Medical segments. The company offers products for interventional cardiology, structural heart, heart failure, peripheral vascular, neurovascular, interventional oncology, electrophysiology, vascular access, infusion therapy, hemodialysis, urology, and gastroenterology procedures. It also provides cardiac rhythm management products, including implantable pacemakers, implantable cardioverter defibrillators, insertable cardiac monitors, implantable cardiac pacing and defibrillation leads, and heart failure therapies; neuromodulation products, such as implantable spinal cord stimulators; and non-rechargeable batteries, feedthroughs, device enclosures, machined components, and lead components and sub-assemblies. In addition, the company offers rechargeable batteries and chargers; and arthroscopic, laparoscopic, and general surgery devices and components, such as harmonic scalpels, shaver blades, burr shavers, radio frequency probes, biopsy probes, trocars, electrocautery components, wound dressings, GERD treatment components, and phacoemulsification needles. Further, it provides orthopedic products that include instruments used in hip, knee, and spine surgeries, as well as reamers and chisels. Additionally, the company offers customized battery power and power management systems, and battery solutions for the energy, military, and environmental markets. Furthermore, the company provides medical technologies. It serves multi-national original equipment manufacturers and their affiliated subsidiaries in the cardiac, neuromodulation, orthopedics, vascular, and advanced surgical and portable medical markets. Integer Holdings Corporation was founded in 1970 and is headquartered in Plano, Texas.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
Integer Holdings Corporation designs and manufactures components, subsystems and devices for medical device OEMs, with major end-market exposure to cardiac rhythm management, electrophysiology and precision surgical technologies. Long-term growth may be supported by aging populations, rising cardiovascular procedures and continued OEM outsourcing to specialized contract manufacturers. The company appears positioned with manufacturing scale and long-term customer relationships that could support recurring revenue and operational leverage.
Material risks include customer concentration and execution risk in complex, highly regulated manufacturing, together with supply-chain disruption sensitivity and exposure to cyclical medical device spending.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Income before tax | 75.96M | 101.06M | 86.21M | 105.19M | 61.12M |
| Net income | 66.38M | 96.81M | 77.26M | 96.34M | 167.96M |
| Selling general administrative | 160.58M | 141.42M | 109.01M | 138.69M | 115.79M |
| Gross profit | 359.01M | 336.97M | 285.71M | 355.01M | 362.67M |
| Reconciled depreciation | 91.99M | 81.37M | 79.32M | 77.89M | 88.99M |
| Ebit | 121.33M | 135.71M | 120.61M | 157.63M | 154.80M |
| Ebitda | 222.76M | 214.06M | 203.75M | 236.11M | 243.79M |
| Depreciation and amortization | 101.44M | 78.35M | 83.14M | 78.47M | 88.99M |
| Non operating income net other | 0.90M | 0.12M | -1.52M | 0.58M | -0.75M |
| Operating income | 121.33M | 135.71M | 120.61M | 157.63M | 155.56M |
| Other operating expenses | 1238.59M | 1085.37M | 952.83M | 1100.46M | 1059.46M |
| Interest expense | 38.63M | 31.63M | 38.22M | 52.55M | 99.31M |
| Tax provision | 10.61M | 8.04M | 8.95M | 13.97M | 14.08M |
| Interest income | - | - | - | 55.52M | - |
| Net interest income | -38.63M | -31.63M | -38.22M | -52.55M | -99.31M |
| Extraordinary items | - | - | - | 5.12M | 109.93M |
| Income tax expense | 10.61M | 8.04M | 8.95M | 13.97M | 14.08M |
| Total revenue | 1376.10M | 1221.08M | 1073.44M | 1258.09M | 1215.01M |
| Total operating expenses | 221.50M | 201.26M | 165.09M | 197.38M | 207.11M |
| Cost of revenue | 1017.09M | 884.11M | 787.74M | 903.08M | 852.35M |
| Total other income expense net | -45.37M | -34.65M | -34.41M | -52.44M | 4.87M |
| Discontinued operations | 1.03M | 3.79M | 3.79M | 5.12M | 188.31M |
| Net income from continuing ops | 65.35M | 93.02M | 77.26M | 91.22M | 47.03M |
| Net income applicable to common shares | 66.38M | 96.81M | 77.26M | 96.34M | 167.96M |
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Total assets | 2794.39M | 2582.22M | 2371.86M | 2353.09M | 2326.68M |
| Intangible assets | 819.89M | 807.81M | 757.22M | 775.78M | 812.34M |
| Other current assets | 27.00M | 27.61M | 15.90M | 17.85M | 15.10M |
| Total liab | 1376.93M | 1227.52M | 1100.80M | 1200.61M | 1266.19M |
| Total stockholder equity | 1417.46M | 1354.70M | 1271.06M | 1152.49M | 1060.49M |
| Deferred long term liab | - | 171.50M | 182.30M | 187.98M | 203.91M |
| Other current liab | 78.81M | 53.88M | 56.19M | 67.12M | 67.40M |
| Common stock | 0.03M | 0.03M | 0.03M | 0.03M | 0.03M |
| Capital stock | 0.03M | 0.03M | 0.03M | 0.03M | 0.03M |
| Retained earnings | 680.70M | 614.32M | 517.52M | 440.26M | 344.50M |
| Other liab | 172.79M | 195.25M | 212.99M | 204.33M | 213.61M |
| Good will | 982.19M | 924.70M | 859.44M | 839.62M | 832.34M |
| Other assets | 17.39M | 49.57M | 88.29M | 11.47M | 7.50M |
| Cash | 24.27M | 17.89M | 49.21M | 13.54M | 25.57M |
| Total current liabilities | 223.75M | 159.63M | 156.19M | 179.08M | 164.57M |
| Current deferred revenue | 5.62M | 3.78M | 2.50M | 1.98M | 2.48M |
| Net debt | 983.41M | 879.87M | 728.34M | 845.86M | 899.94M |
| Short term debt | 28.55M | 25.11M | 45.93M | 45.01M | 37.50M |
| Short long term debt | 18.19M | 15.25M | 37.50M | 37.50M | 37.50M |
| Short long term debt total | 1007.68M | 897.75M | 777.55M | 859.39M | 925.51M |
| Other stockholder equity | 731.39M | 713.15M | 700.81M | 692.21M | 682.96M |
| Property plant equipment | 317.24M | 347.15M | 253.96M | 246.19M | 231.27M |
| Total current assets | 558.30M | 452.98M | 412.94M | 415.39M | 416.25M |
| Long term investments | - | - | - | 22.26M | 26.99M |
| Net tangible assets | 1417.46M | -377.82M | -345.61M | -462.91M | -584.18M |
| Net receivables | 298.25M | 251.79M | 198.51M | 216.75M | 185.50M |
| Long term debt | 907.07M | 812.88M | 693.76M | 777.27M | 888.01M |
| Inventory | 208.77M | 155.70M | 149.32M | 167.26M | 190.08M |
| Accounts payable | 110.78M | 76.86M | 51.57M | 64.97M | 57.19M |
| Accumulated other comprehensive income | 5.33M | 27.19M | 52.69M | 19.99M | 33.00M |
| Common stock total equity | 0.03M | 0.03M | 0.03M | 0.03M | 0.03M |
| Retained earnings total equity | 680.70M | 614.32M | 517.52M | 440.26M | 344.50M |
| Treasury stock | - | - | - | -8.81M | -8.12M |
| Non currrent assets other | 26.86M | 43.86M | 38.74M | 29.30M | 30.55M |
| Non current assets total | 2236.09M | 2129.23M | 1958.92M | 1937.70M | 1910.43M |
| Capital lease obligations | 82.42M | 69.63M | 46.29M | 44.62M | - |
| Long term debt total | - | 812.88M | 693.76M | 777.27M | 888.01M |
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Investments | 0.30M | -271.00M | -56.58M | -58.86M | 536.67M |
| Change to liabilities | 29.03M | 19.52M | -24.12M | -5.82M | -11.64M |
| Total cashflows from investing activities | -200.42M | -271.00M | -56.58M | -58.86M | 536.67M |
| Net borrowings | 95.75M | 95.59M | -88.02M | -117.89M | -732.46M |
| Total cash from financing activities | 92.48M | 81.99M | -88.58M | -117.93M | -725.08M |
| Change to operating activities | -8.77M | -25.39M | -11.59M | -33.80M | -3.23M |
| Net income | 66.38M | 96.81M | 77.26M | 96.34M | 167.96M |
| Change in cash | 6.39M | -31.32M | 35.67M | -12.03M | -18.53M |
| Begin period cash flow | 17.89M | 49.21M | 13.54M | 25.57M | 44.10M |
| End period cash flow | 24.27M | 17.89M | 49.21M | 13.54M | 25.57M |
| Total cash from operating activities | 116.38M | 156.67M | 181.34M | 165.36M | 167.30M |
| Depreciation | 91.99M | 81.37M | 79.32M | 77.89M | 88.99M |
| Other cashflows from investing activities | -126.00M | -217.53M | -9.74M | -10.66M | 581.58M |
| Change to inventory | -56.72M | 4.70M | 18.44M | 3.72M | -16.09M |
| Change to account receivables | -41.38M | -17.54M | 38.15M | -6.98M | 9.29M |
| Sale purchase of stock | 0.15M | 0.74M | 3.26M | 3.24M | 12.41M |
| Other cashflows from financing activities | 163.42M | 886.94M | 183.93M | 32.57M | -19.61M |
| Change to netincome | 13.27M | 19.28M | 0.80M | -6.13M | -123.22M |
| Capital expenditures | 74.73M | 53.46M | 51.44M | 48.20M | 44.91M |
| Change receivables | -41.38M | -17.54M | 38.15M | -6.98M | 9.29M |
| Cash flows other operating | 11.77M | -16.30M | -13.29M | -1.45M | 2.90M |
| Exchange rate changes | - | - | - | - | 2.58M |
| Cash and cash equivalents changes | 8.44M | -32.35M | 36.19M | -11.43M | -18.53M |
| Change in working capital | -75.85M | -47.74M | 16.16M | -40.13M | -9.92M |
| Stock based compensation | 21.02M | 16.18M | 9.16M | 9.29M | 10.47M |
| Other non cash items | 30.34M | 20.32M | 6.40M | 32.25M | -151.33M |
| Free cash flow | 41.65M | 103.20M | 129.90M | 117.16M | 122.39M |
Sector: Healthcare Industry: Medical Devices
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| ITGR Integer Holdings Corp |
0.02 0.02% |
126.70 | 40.77 | 18.80 | 2.13 | 2.22 | 2.72 | 16.94 |
| ABT Abbott Laboratories |
-0.71 0.65% |
108.58 | 25.97 | 17.24 | 3.57 | 3.20 | 3.81 | 16.75 |
| MDT Medtronic PLC |
0.28 0.28% |
101.89 | 26.60 | 15.87 | 3.35 | 2.08 | 3.90 | 14.12 |
| SYK Stryker Corporation |
-2.16 0.68% |
316.63 | 29.23 | 16.86 | 4.18 | 4.51 | 4.63 | 17.16 |
| SEMHF Siemens Healthineers AG |
- -% |
47.31 | 39.57 | 21.32 | 3.01 | 3.29 | 2.95 | 16.92 |
Integer Holdings Corporation operates as a medical device outsource manufacturer in the United States, Puerto Rico, Costa Rica, and internationally. It operates through Medical and Non-Medical segments. The company offers products for interventional cardiology, structural heart, heart failure, peripheral vascular, neurovascular, interventional oncology, electrophysiology, vascular access, infusion therapy, hemodialysis, urology, and gastroenterology procedures. It also provides cardiac rhythm management products, including implantable pacemakers, implantable cardioverter defibrillators, insertable cardiac monitors, implantable cardiac pacing and defibrillation leads, and heart failure therapies; neuromodulation products, such as implantable spinal cord stimulators; and non-rechargeable batteries, feedthroughs, device enclosures, machined components, and lead components and sub-assemblies. In addition, the company offers rechargeable batteries and chargers; and arthroscopic, laparoscopic, and general surgery devices and components, such as harmonic scalpels, shaver blades, burr shavers, radio frequency probes, biopsy probes, trocars, electrocautery components, wound dressings, GERD treatment components, and phacoemulsification needles. Further, it provides orthopedic products that include instruments used in hip, knee, and spine surgeries, as well as reamers and chisels. Additionally, the company offers customized battery power and power management systems, and battery solutions for the energy, military, and environmental markets. Furthermore, the company provides medical technologies. It serves multi-national original equipment manufacturers and their affiliated subsidiaries in the cardiac, neuromodulation, orthopedics, vascular, and advanced surgical and portable medical markets. Integer Holdings Corporation was founded in 1970 and is headquartered in Plano, Texas.
| Name | Title | Year Born |
|---|---|---|
| Mr. Joseph W. Dziedzic | Pres, CEO & Director | 1968 |
| Mr. Jason K. Garland | Exec. VP & CFO | 1974 |
| Ms. Jennifer M. Bolt | Exec. VP of Global Operations & ESG | 1969 |
| Mr. Payman Khales | Pres of Cardio & Vascular | 1970 |
| Mr. Anthony W. Borowicz | Sr. VP of Investor Relations | 1957 |
| Mr. McAlister C. Marshall II | Sr. VP, Gen. Counsel, Chief Ethics & Compliance Officer and Corp. Sec. | 1970 |
| Mr. Kirk K. Thor | Exec. VP & Chief HR Officer | 1964 |
| Mr. Carter Houghton | Pres of Electrochem & Power Solutions | 1969 |
| Ms. Margaret Carthy | Sr. VP of Quality & Regulatory Affairs | 1964 |
| Mr. Andrew Senn | Sr. VP of Strategy and Bus. Devel. | NA |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.